Unipolar Depression | Disease Landscape & Forecast | Major Depressive Disorder | G7 | 2022

The unipolar depression therapy market is crowded and highly genericized. The prominent use of drugs such as selective serotonin reuptake inhibitors (SSRIs) as early-line treatments contributes to the challenges that branded therapies face when entering this market. Newer-to-market brands (e.g., Lundbeck / Takeda’s Trintellix / Brintellix, Lundbeck / Otsuka Pharmaceutical’s Rexulti / Rxulti) largely compete for use in inadequate responders / treatment-resistant depression (TRD) patients; TRD patients make up one-third of the major depressive disorder (MDD) population. The most recent entrant to the depression market, Janssen’s Spravato, has the fastest onset of therapeutic effect among the approved therapies—fulfilling a key unmet need—but its use for TRD is constrained by multiple factors. Because of the substantial remaining unmet need in MDD treatment, physicians will continue to look to emerging therapies—many of which offer novel mechanisms of action—as potential treatments in this market.


  • What is the current size of the MDD therapy market in the G7 countries? What key events will influence the market over the next decade?
  • What factors drive and constrain the use of branded antidepressants and atypical antipsychotics in MDD? What branded therapy is expected to experience the most commercial success during the forecast period?
  • What are the areas of most unmet need in the treatment of unipolar depression? Which late-phase therapies have the potential to fulfill these needs?
  • What improvements would key late-phase therapies need to demonstrate in order to compete effectively in this crowded market? Where will these agents be placed in the treatment algorithm?


Geographies: United States, France, Germany, Italy, Spain, United Kingdom, Japan.

Primary research: 26 country-specific interviews with thought-leading psychiatrists; supported by survey data collected for this and other Clarivate research.

Epidemiology: Prevalence of MDD by country; diagnosed / drug-treated prevalence of MDD by country.

Forecast: 10-year, annualized, drug-level sales and patient share of key MDD therapies in 2021-2031, segmented by brands / generics.

Emerging therapies: Phase III/PR: 7 drugs. Coverage of select early-phase products.


Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.


Disease Landscape & Forecast will feature continual updates in 2022 to provide timely insights and analyses as meaningful indication-specific news and events unfold.

Additionally, Disease Landscape & Forecast introduces a new Drug Pipeline chapter with real-time, global pipeline intelligence content directly from Cortellis. This chapter is updated daily and features interactive figures that can be easily downloaded for detailed analysis or presentations.

Login to access report